J. Fernando Arevalo, MD, PhD, FACS
Show Description +
J. Fernando Arevalo, MD, PhD, FACS, explains the indication for brolucizumab (Beovu, Novartis) and details the findings from the parallel phase 3 HAWK and HARRIER trials, which evaluated brolucizumab in patients with wet age-related macular degeneration.
Posted: 10/23/2019
J. Fernando Arevalo, MD, PhD, FACS
J. Fernando Arevalo, MD, PhD, FACS, explains the indication for brolucizumab (Beovu, Novartis) and details the findings from the parallel phase 3 HAWK and HARRIER trials, which evaluated brolucizumab in patients with wet age-related macular degeneration.
Posted: 10/23/2019
Bryn Mawr Communications, LLC, and Eyetube.net are not affiliated with the official program of AAO: 2019.
Please log in to leave a comment.